pharmaphorum

UCB bags FDA okay for first drug to treat rare disease TK2d

Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. People living with thymidine kinase 2 ...
pharmaphorum

UCB brings first therapy for rare disease TK2d to EU

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, after the European Commission cleared the drug "under exceptional ...
PharmiWeb

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

“The approval of doxecitine and doxribtimine represents a pivotal moment for the TK2d community who previously had no FDA-approved treatment options for this rare genetic mitochondrial disease beyond ...
GEN

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare (1.64 cases per 1,000,000 people) often fatal, genetic mitochondrial disease characterized by progressive and severe muscle weakness. Those ...
MM&M

The long road to yes: How years of persistence finally led to a treatment for ultra-rare TK2d deficiency

Genetically precise, but therapeutically untouchable. Thymidine kinase 2 deficiency (TK2d) has hid in a clinical blind spot for most of the time since scientists first identified it in 2001. Families ...
Investing

FDA approves first treatment for rare genetic disease TK2d

ATLANTA - The U.S. Food and Drug Administration has approved KYGEVVI (doxecitine and doxribtimine) as the first treatment for thymidine kinase 2 deficiency (TK2d), UCB announced Monday. The ...
manilatimes

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and ...

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 - The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA approval ...
Mena FN

FDA Approves KYGEVVI® (Doxecitine And Doxribtimine), The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d), A Rare And ...

(MENAFN- GlobeNewsWire - Nasdaq) This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes progressive muscle weakness impairing ...
Finanznachrichten

UCB: U.S. FDA approves KYGEVVI (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Approved indication: KYGEVVI ® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients ...
Finanznachrichten

U.S. FDA approves KYGEVVI (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

The KYGEVVI approval is supported by safety and efficacy data from one Phase 2 clinical study, two retrospective chart review studies, and an expanded access use program*. 1,8,9,10,11 These studies ...